Lyra Therapeutics Inc expected to post a loss of 59 cents a share - Earnings Preview

Lyra Therapeutics

04/08/2021 03:51

* Lyra Therapeutics Inc  LYRA.OQ   LYRA.O  is expected to show a
no change in quarterly revenue when it reports results on August
3 (estimated). 
​* Refinitiv's mean analyst estimate for Lyra Therapeutics Inc
is for a loss of 59 cents per share. For the same quarter last
year, the company reported a loss of 56 cents per share.
* The current average analyst rating on the shares is "strong
buy" and the breakdown of recommendations is 4 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell." 
* The mean earnings estimate of analysts was unchanged in the
last three months. ​
* Wall Street's median 12-month price target for Lyra
Therapeutics Inc is $26​, about 76.5% above​ its last closing
price of $6.11. ​​​
* Previous quarterly performance (using preferred earnings
measure in US dollars). ​
 QUARTER       STARMINE    REFINITIV  ACTUAL    BEAT,   SURPRI
 ENDING        SMARTESTIM  IBES                 MET,    SE %
               ATE®        ESTIMATE             MISSED  
 Mar. 31 2021  -0.48       -0.48      -0.60     Missed  -25
 Dec. 31 2020  -0.59       -0.56      -0.46     Beat    17.9
 Sep. 30 2020  -0.38       -0.41      -0.49     Missed  -20.5​
 Jun. 30 2020  -0.38       -0.38      -0.56     Missed  -48.7
 Mar.          -0.67​      -0.67      -18.70    Missed  -2,691
 31​ 2020​                                              ​
                                                        ​
 This summary was machine generated August 4 at 02:50 GMT.  All
figures in US dollars unless otherwise stated